Leishmaniasis is caused by parasitic protozoa of the genus Leishmania which, in the infected host are obliging intracellular parasite . Montanide ISA 70 is an adjuvant composed of a natural metabolizable oil and a highly refined emulsifier from the manide monooleate family. The TSA (thiol-specific antioxidant) is a considerable antigen of Leishmania major. The purpose of this work was Protein-vaccine efficacy in the presence Montanide comparing to absence of it. The expression of recombinant protein was confirmed with SDS (sodium dodecyl sulfate) page and Western bloting . 48 BALB/c mice were divided into four groups [TSA/Freund ,TSA/Alum+BCG , TSA/ Montanide and PBS groups] and immunized with 20 mg of vaccine subcutaneously three times intervals on days 0, 14 and 28. The mice were challenged with parasite 21 days after final immunization . The lymphocyte proliferation was evaluated with Brdu method. Cytokines was evaluated with ELISA method. The vaccine formulated with the recombinant TSA protein with Montanide induced lymphocytes proliferation , cytokines as compared with the control group. Base on results, current candidate vaccine has potency for futher studies.